60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Forecast
SXTP analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 2 analysts
- Price target
- $3.70 average of analyst targets
- Upside to target
- +332.7% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.73
- 52-week range
- $0.85 – $6.00
SXTP analyst ratings
2 analystsNumber of analysts at each rating.
SXTP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SXTP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.85 | −$0.85 | −$0.85 | −$2.53 | +66.4% | 1 |
| Current fiscal year (2026) | −$3.45 | −$3.45 | −$3.45 | −$11.13 | +69.0% | 1 |
| Next fiscal year (2027) | −$3.58 | −$3.58 | −$3.58 | −$3.45 | −3.8% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SXTP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $270,000 | $270,000 | $270,000 | −48.9% | 1 |
| Current fiscal year (2026) | $1.0M | $1.0M | $1.0M | −0.5% | 2 |
| Next fiscal year (2027) | $1.7M | $1.4M | $2.0M | +70.0% | 2 |
SXTP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SXTP revenue: reported and forecast
SXTP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.96 | −$1.96 | −$0.79 | −$0.79 | −$0.85 | −56.6% | 0 up · 1 down |
| Current fiscal year (2026) | −$7.88 | −$7.88 | −$3.18 | −$3.18 | −$3.45 | −56.2% | 0 up · 1 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | $0.00 | −$3.58 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SXTP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SXTP beat in 3 of 12.
What analysts expect from SXTP
2 analysts cover 60 Degrees Pharmaceuticals; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.70, 332.7% above the latest close of $0.85. Analysts expect earnings of −$3.45 per share for 2026, +69.0% from a year earlier. For 2027 the average estimate is −$3.58 per share on revenue of $1.7 million. 60 Degrees Pharmaceuticals beat the EPS estimate in 3 of the last 12 quarters.
Related: SXTP income statement, SXTP key metrics, SXTP chart. See the SXTP stock overview for the latest quote and news.
SXTP forecast FAQ
What is 60 Degrees Pharmaceuticals's price target?
The average analyst price target for 60 Degrees Pharmaceuticals is $3.70, 332.7% above the latest close of $0.85.
Is 60 Degrees Pharmaceuticals a buy, hold or sell?
Of 2 analysts covering 60 Degrees Pharmaceuticals, 1 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is 60 Degrees Pharmaceuticals's EPS forecast?
Analysts forecast −$3.45 per share for 2026 (range −$3.45 to −$3.45); for 2027 the estimate is −$3.58.
What is 60 Degrees Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $1.0 million, growth of −0.5%; for 2027 it is $1.7 million.
When does 60 Degrees Pharmaceuticals report earnings?
60 Degrees Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.73.
Does 60 Degrees Pharmaceuticals usually beat earnings estimates?
60 Degrees Pharmaceuticals reported EPS at or above the analyst estimate in 3 of the last 12 quarters.